Team

Michael S. Kim founded Octave Ventures (US) in 2018 to make venture investments in ​primarily biotech and deep tech companies. Michael has over 30 years of experience in principal investing and investment banking which he uses to help advise the next generation of entrepreneurs and leaders.  Prior to forming Octave, Michael started his career as a mortgage trader in New York with Merrill Lynch and Morgan Stanley. He has forged strong relationships with major corporations, institutional investors, and sovereign wealth funds. He sits on the board of eight of Octave’s portfolio companies​, including Cornami, General Radar, Osaro, and four start-ups founded through Johns Hopkins Medical School (D&D Pharmatech, Precision Molecular, ValTed Seq, and Plenary.AI). Michael is also the co-founder of Evia Life Sciences, which develops diagnostics and therapeutics in the area of exosomes with Takahiro Ochiya, Head of Molecular and Cellular Medicine at the National Cancer Center of Japan. Michael received his B.A. in Economics from the University of Chicago.

Josh’s career has included significant time both in private practice at international law firms and front office positions at global financial institutions. Josh has significant experience with fund formation, cross-border capital markets, structured finance and private equity transactions, including serving as the head of Japan for the Partner Asset Facility at Credit Suisse, a debt and special situations fund that grew investor equity to approximately US$1.9 billion. He has spent  the majority of his career in Asia across Japan, Korea and Hong Kong. Josh graduated from the University of California at Berkeley and Yale Law School.